Advances in biomarkers in multiple system atrophy

In order to improve illnessidentification, monitoring, and patient outcomes, this special reportemphasizes the revolutionary potential of fluid and imaging biomarkers usingnew diagnostic technologies in Multiple system atrophy (MSA). Innovations like multiplexseeding aggregation assays (SAA), 18FDG-Positron Emission Tomography (PET), andSPECT are changing the diagnostic landscape. These techniques make it easier todetect MSA early and offer noninvasive monitoring choices. Althoughneurofilament light chain measurements in blood and cerebrospinal fluid (CSF),as well as α-synuclein-baseddiagnostic biomarkers in CSF, are recognized as both diagnostic and surrogatemarkers of disease progression in MSA, their application in clinical practiceis limited to research. Some efforts are being made in the development ofselective α- synucleinPET tracers despite numerous barriers in visualizing intracellular localizationof α-synuclein. The primarydrawbacks include the high expense of SAA and imaging technologies, the paucityof multicenter longitudinal investigations, and the lack of uniformity of theprοtocols. The research highlights that to successfully solve these restrictions, stakeholders must continue tocollaborate. A multi-dimensional biomarkersystem of MSA patients maximizes the power of contemporary diagnostics toenhance MSA care by prioritizing the ongoing evaluation of multi-omics data.